The Section on Clinical Brain Imaging has made a sustained effort to use positron emission tomography (PET) to help elucidate the neural mechanisms and pathophysiology of psychiatric disorders. The major focus of the Section over the past year has been directed at using PET to address questions about Attention-Deficit Hyperactivity Disorder (ADHD) in adult and teenage subjects. PET studies related to ADHD were conducted in three areas: Stimulant effects Studies were completed on the cerebral metabolic effects of chronic dextroamphetamine and methylphenidate treatment. Both stimulants appear to have modest metabolic effects in the brain while producing positive behavioral improvement. Studies on the cerebral metabolic effects of intravenous administration of dextroamphetamine were begun. Development PET studies on normal teenagers and those with ADHD are continuing. A new method, which allows minors to be scanned with minimal radiation exposure, is being employed and the initial description of the procedure has been published. In addition, teenagers with schizophrenia are being scanned by our Section using the new method. Thyroid Resistance Symptoms of ADHD are highly associated with generalized resistance to thyroid hormone, a disorder with a defined genetic defect. Preliminarily PET studies show impaired attention and reduced metabolism in the parietal lobe in adults with thyroid resistance. The Section has completed studies on scopolamine as a model for the memory impairment in Alzheimer~s Disease using PET. A clinical trial of the effectiveness of deprenyl in adults with ADHD was started. The Section is continuing work on the development of F-DOPA methodology, which is now extended to human subjects after initial work with nonhuman primates. Cyclofoxy PET scanning methodology is being applied to various patient groups. Using primate model, studies are continuing on metabolic effects of cocaine and fluphenazine. Finally, the Section is continuing its mission to train other research groups in the use of PET imaging technology and data analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH000507-11
Application #
3781326
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1993
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cohen, Robert M; Szczepanik, Joanna; McManus, Michael et al. (2006) Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiol Aging 27:1385-94
Cannon-Spoor, H Eleanor; Levy, James A; Zubenko, George S et al. (2005) Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 13:312-8
Toyama, Hiroshi; Ye, Daniel; Ichise, Masanori et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
Levy, James A; Bergeson, Judy; Putnam, Karen et al. (2004) Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. J Int Neuropsychol Soc 10:362-70
Sunderland, Trey; Mirza, Nadeem; Putnam, Karen T et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56:670-6
Podruchny, Teresa A; Connolly, Catherine; Bokde, Arun et al. (2003) In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44
Cohen, Robert M; Podruchny, Teresa A; Bokde, Arun L W et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49:150-6
Doudet, D J; Holden, J E; Jivan, S et al. (2000) In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 38:105-13
Elkashef, A M; Doudet, D; Bryant, T et al. (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:11-Jan
Wyatt, R J; Henter, I D; Bartko, J J (1999) The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 46:1092-105

Showing the most recent 10 out of 11 publications